Media headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have trended positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.0195889738483 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of Intercept Pharmaceuticals (ICPT) opened at $62.87 on Friday. The firm has a market cap of $1,600.00, a P/E ratio of -4.25 and a beta of -2.13. Intercept Pharmaceuticals has a one year low of $51.53 and a one year high of $135.59. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. The company had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. Intercept Pharmaceuticals’s revenue was up 697.9% compared to the same quarter last year. During the same period last year, the firm earned ($3.59) earnings per share. equities research analysts anticipate that Intercept Pharmaceuticals will post -13.38 EPS for the current year.

A number of equities analysts have recently issued reports on ICPT shares. Seaport Global Securities reiterated a “buy” rating and set a $136.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. Goldman Sachs Group reiterated a “neutral” rating and set a $79.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. Bank of America dropped their price objective on shares of Intercept Pharmaceuticals from $102.00 to $73.00 and set an “underperform” rating on the stock in a research note on Friday, October 13th. Oppenheimer reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, October 24th. Finally, Laidlaw upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research note on Wednesday, November 1st. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and an average target price of $134.86.

ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/intercept-pharmaceuticals-icpt-receives-coverage-optimism-score-of-0-26/1841128.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.